GE HealthCare Technologies Inc. (NASDAQ:GEHC) Stake Boosted by Pinnacle Bancorp Inc.

Pinnacle Bancorp Inc. lifted its stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 107.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 771 shares of the company’s stock after acquiring an additional 400 shares during the quarter. Pinnacle Bancorp Inc.’s holdings in GE HealthCare Technologies were worth $60,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of GEHC. Quent Capital LLC raised its stake in shares of GE HealthCare Technologies by 18.4% during the 3rd quarter. Quent Capital LLC now owns 766 shares of the company’s stock worth $72,000 after purchasing an additional 119 shares in the last quarter. Greenleaf Trust increased its holdings in GE HealthCare Technologies by 1.7% in the third quarter. Greenleaf Trust now owns 7,619 shares of the company’s stock worth $715,000 after buying an additional 124 shares during the last quarter. Westside Investment Management Inc. raised its position in GE HealthCare Technologies by 32.0% during the third quarter. Westside Investment Management Inc. now owns 516 shares of the company’s stock valued at $48,000 after acquiring an additional 125 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in GE HealthCare Technologies by 8.7% in the second quarter. EverSource Wealth Advisors LLC now owns 1,590 shares of the company’s stock valued at $135,000 after acquiring an additional 127 shares during the last quarter. Finally, Quarry LP grew its position in GE HealthCare Technologies by 28.3% in the second quarter. Quarry LP now owns 594 shares of the company’s stock worth $46,000 after acquiring an additional 131 shares in the last quarter. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other GE HealthCare Technologies news, CEO Roland Rott sold 3,577 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $86.48, for a total transaction of $309,338.96. Following the completion of the transaction, the chief executive officer now owns 24,298 shares in the company, valued at $2,101,291.04. This trade represents a 12.83 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.27% of the company’s stock.

GE HealthCare Technologies Stock Performance

NASDAQ GEHC opened at $85.00 on Friday. The company’s fifty day moving average is $82.07 and its two-hundred day moving average is $84.26. GE HealthCare Technologies Inc. has a 52-week low of $71.31 and a 52-week high of $94.55. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.23 and a quick ratio of 0.98. The firm has a market capitalization of $38.83 billion, a price-to-earnings ratio of 23.35, a P/E/G ratio of 2.80 and a beta of 1.11.

GE HealthCare Technologies (NASDAQ:GEHC) last released its earnings results on Wednesday, October 30th. The company reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of $1.06 by $0.08. The business had revenue of $4.86 billion for the quarter, compared to the consensus estimate of $4.87 billion. GE HealthCare Technologies had a return on equity of 25.19% and a net margin of 8.56%. The firm’s revenue for the quarter was up .9% compared to the same quarter last year. During the same period last year, the business earned $0.99 earnings per share. Equities research analysts forecast that GE HealthCare Technologies Inc. will post 4.3 EPS for the current year.

GE HealthCare Technologies Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Investors of record on Tuesday, January 14th will be given a $0.035 dividend. This is a boost from GE HealthCare Technologies’s previous quarterly dividend of $0.03. This represents a $0.14 annualized dividend and a yield of 0.16%. The ex-dividend date of this dividend is Tuesday, January 14th. GE HealthCare Technologies’s dividend payout ratio (DPR) is 3.30%.

Analysts Set New Price Targets

GEHC has been the topic of a number of recent research reports. Jefferies Financial Group upgraded shares of GE HealthCare Technologies from a “hold” rating to a “buy” rating and raised their price target for the company from $95.00 to $103.00 in a report on Wednesday, January 8th. Stifel Nicolaus boosted their price target on GE HealthCare Technologies from $100.00 to $102.00 and gave the stock a “buy” rating in a research report on Monday, September 30th. UBS Group lowered GE HealthCare Technologies from a “neutral” rating to a “sell” rating and lowered their price objective for the company from $84.00 to $74.00 in a report on Thursday, September 26th. Wells Fargo & Company boosted their target price on GE HealthCare Technologies from $95.00 to $96.00 and gave the stock an “overweight” rating in a report on Thursday, October 31st. Finally, Evercore ISI increased their price target on GE HealthCare Technologies from $98.00 to $102.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $96.00.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.